Brazil drives awareness of Notivisa adverse events reporting programme:
This article was originally published in Clinica
Executive Summary
Brazil's healthcare products regulatory agency, Anvisa, is continuing its efforts to raise awareness of its new Notivisa healthcare vigilance and surveillance programme (see Clinica No 1198, p 13). The Brasilia-based agency hosted yesterday, in Sao Paulo city, the conference "Notivisa, a new paradigm in healthcare vigilance". Focusing specifically on the electronic reporting of adverse events and technical faults involving medical products, the meeting was addressed primarily at the medical staff and healthcare industry bodies and associations in three of the country's five regions, namely the south, southeast and centrewest.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.